News Harm Reduction Therapeutics In The News The latest stories and news about Harm Reduction Therapeutics and naloxone Harm Reduction Therapeutics Inc. doesn’t have to make an advisory committee presentation for its proposal for an OTC naloxone nasal spray, but still must wait for a US Food and Drug Administration decision it’s confident will be for approval. The FDA on 1 March announced it cancelled the meeting of its Nonprescription Drug and Anesthetic and Analgesic Drug Products advisory committees to consider HRT’s new drug application for a 3-mg naloxone nasal spray scheduled 20 March. “The meeting is no longer needed,” the agency states in the announcement scheduled for publication in the Federal Register on 2 March. Mar 2, 2023 Drug companies could have made naloxone more accessible. Why didn’t they? Jan 23, 2023 FDA Fast-Tracks Review of Overdose Drug Naloxone for Use Without Prescription Jan 3, 2023 New Drug Application for RiVive™ Over-the-Counter Naloxone Nasal Spray Accepted and Granted Priority Review by FDA Jan 3, 2023 US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals Nov 2, 2022 OTC Naloxone One Step Closer as Harm Reduction Therapeutics Initiates a Rolling Submission of its New Drug Application to U.S. FDA for RiVive™ for Emergency Treatment of Opioid Overdose Oct 11, 2022 Harm Reduction Therapeutics Signs Commercial Supply Agreement for Fast Tracked Naloxone Nasal Spray to Reverse Opioid Overdoses Aug 11, 2022 Harm Reduction Therapeutics Announces that its Naloxone Nasal Spray Met its Primary Endpoints in a Phase 1 Clinical Trial Mar 1, 2022 What’s Taking So Long for Naloxone to Be Made Available Over the Counter? Jan 18, 2019 Load More
